Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

I/O + Chemotherapy Treatments for Endometrial Carcinoma

March 18th 2022

A review of data from several clinical trials on the use of I/O + chemotherapy as treatment for endometrial carcinoma.

Endometrial Carcinoma: Clinical Case Scenario 2

March 18th 2022

Experts explain the need for germline testing and genetic counseling for patients with endometrial carcinoma as demonstrated by a patient case.

Selinexor Maintenance Improves PFS in Advanced or Recurrent Endometrial Cancer, Particularly p53 Wild-Type Subset

March 18th 2022

Selinexor reduced the risk of disease progression or death by 30% in an audited intent-to-treat population of patients with advanced or recurrent endometrial cancer who received frontline chemotherapy, and by 62% in a subset of patients with p53 wild-type disease, according to data from the phase 3 SIENDO trial.

Molecular Testing in Endometrial Cancer

March 15th 2022

Experts discuss how molecular testing can inform treatment selection and patient management for those with endometrial cancer.

Endometrial Cancer: A Global Problem

March 15th 2022

Vicky Makker, MD and Ramez Eskander, MD discuss the increasing global incidence of endometrial cancer.

Dr. Olawaiye on the Social and Biological Determinants of Disparities in Women’s Cancer

March 12th 2022

Alexander B. Olawaiye, MD, discusses the social and biological determinants of disparities in women’s cancer.

Sintilimab/Anlotinib Produces Meaningful Responses in PD-L1+ Recurrent or Metastatic Cervical Cancer

March 11th 2022

The addition of anlotinib to sintilimab appeared to be efficacious and safe when used as a second- or later-line treatment in patients with PD-L1–positive, recurrent or metastatic cervical cancer.

Dose Reduction in Endometrial Carcinoma Treatment

March 10th 2022

Drs Bradley Monk and David O’Malley explain dose reduction in endometrial carcinoma treatment based on clinical trial data.

Treatment Options for Advanced Stage Relapsed Endometrial Carcinoma

March 10th 2022

Physician-researchers discuss the risk of recurrence in endometrial carcinoma and the available treatment options after relapse.

Biomarker Testing in Endometrial Carcinoma

March 4th 2022

An overview of biomarker testing in endometrial carcinoma.

Endometrial Carcinoma: Clinical Scenario 1

March 4th 2022

Oncologists describe a typical presentation of endometrial carcinoma and debate the implications of radiation treatment.

Paclitaxel/Carboplatin Noninferior to Paclitaxel/Ifosfamide in Uterine Carcinosarcoma

March 2nd 2022

The addition of carboplatin to paclitaxel prolonged overall survival and progression-free survival, and proved to be noninferior to the standard combination of paclitaxel and ifosfamide in patients with uterine carcinosarcoma.

Bob the Builder: Robert C. Young Is Giant of Cancer Care in Gynecologic Cancer

February 21st 2022

"If you stay at home too long, with too narrow a focus, you lose sight of what’s happening in the world."

Dr. Brown on the Benefits of Minimally Invasive Surgery in Ovarian Cancer

February 17th 2022

Jubilee Brown, MD, discusses the benefits of minimally invasive surgery in ovarian cancer.

Objectively Accurate Interpretation of Clinical Trials Results Poses a Challenge

February 15th 2022

Much has been written regarding the essential role of clinical trials in the major advances in cancer therapy and observed improvement in disease-related morbidity and mortality.

Frontline Selinexor Maintenance Improves PFS in Advanced or Recurrent Endometrial Cancer

February 8th 2022

Frontline maintenance treatment with selinexor resulted in a statistically significant improvement in median progression-free survival vs placebo in patients with advanced or recurrent endometrial cancer, meeting the primary end point of the phase 3 SIENDO trial.

Virtual Surveillance Visits with Symptom, Serum CA-125 Review May Offer Alternative for Ovarian Cancer Recurrence Detection.

February 1st 2022

In patients with ovarian cancer and pretreatment elevated CA-125 who achieved remission after frontline therapy, most recurrences are detected by rising CA-125 levels or symptoms.

Dr. Olawaiye on Investigating Balstilimab Plus Zalifrelimab in Gynecologic Cancers

February 1st 2022

Alexander Babatunde Olawaiye, MD, discusses the investigation of balstilimab plus zalifrelimab in gynecologic cancers.

Immunotherapy Approvals Signal a Need for Molecular Testing in Endometrial Cancer

January 31st 2022

Sarah Lee, MD, MBA, discusses the use of checkpoint inhibitors in endometrial cancer, research regarding the association between MSI-H, dMMR, and TMB-H disease, and the importance of broad molecular testing to ensure all eligible patients are appropriately matched to immunotherapeutic options.

Increasing Rate of High-Risk Endometrial Cancer in Black Women Prompts Questions Into Underlying Causes

January 30th 2022

Cortney Eakin, MD, discusses alarming trends in uterine cancer histologies in Black women and some of the potential underlying risk factors at play.